| cisplatin / Generic mfg. |
NCT05677217: Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | CHA University | Locally Advanced Cholangiocarcinoma | 09/24 | 11/24 | | |
NCT04365049: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | Radiotherapy, Nab-paclitaxel, Gemcitabine, Camrelizumab | Sun Yat-sen University | PDAC - Pancreatic Ductal Adenocarcinoma | 12/23 | 12/23 | | |
NCT05740995: Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 40 | RoW | neoadjuvant anti-PD-1 plus chemotherapy | Shanghai Zhongshan Hospital | Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | 12/23 | 12/28 | | |
ASSURE, NCT03306901: Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 240 | RoW | Esophagectomy, 5-fluorouracil, 5-FU, Cisplatin, Radiation therapy | Samsung Medical Center, Ministry of Health & Welfare, Korea | Esophageal Cancer | 12/25 | 12/33 | | |
| Recruiting | N/A | 42 | US | Radiation Therapy, radiotherapy, RT, Cetuximab, Erbitux, Chemotherapy, Cisplatin, Immunotherapy, pembrolizumab, Keytruda, nivolumab, Opdivo, durvalumab, Imfinzi | Loren Mell, MD | Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma | 12/23 | 12/24 | | |
ChiCTR2000037472: An open labeled, randomized controlled phase II pilot trial of systematic treatment with or without SBRT in the management of gynecologic cancer with first line chemotherapy induced oligo metastasis |
|
|
| Not yet recruiting | N/A | 120 | | paclitaxel plus cisplatin or carboplatin with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin + PD-1 checkpoint inhibitor with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin with or without Bevacizumab, combined oligo-metastasis SBRT ;paclitaxel plus cisplatin or carboplatin+PD-1 checkpoint inhibitor with or without Bevacizumab, combined oligo-metastasis SBRT | Shanghai First Maternity and Infant Hospital; Shanghai First Maternity and Infant Hospital, Shanghai Hospital Development Center | Gyenecological cancer | | | | |
ChiCTR2000041332: A Study of Camrelizumab, Etopside and Cisplatin Combined Radiotherapy in the Treatment of Patients with Limited Stage Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | N/A | 30 | | combination of camrelizumab、etoposide and cisplatin concurrent with radiotherapy | Beijing Cancer Hospital; Beijing Cancer Hospital, Jiangsu Hengrui Medicine Co.,Ltd. | Small Cell Lung Cancer | | | | |
ChiCTR2100041900: Effect of acupuncture on nausea and vomiting induced by cisplatin chemotherapy during pelvic external irradiation for gynecological tumors |
|
|
| Recruiting | N/A | 54 | | Acupuncture + standard antiemetic drugs ;standard antiemetic drugs | Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, self-raised | Chemoradiotherapy associated nausea and vomiting | | | | |
ChiCTR2100043195: Phase II Trial of Neoadjuvant Tislelizumab combined with chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) Patients |
|
|
| Recruiting | N/A | 30 | China | tislelizumab with gemcitabine-cisplatin (GC) | Chinese PLA General Hospital ; Chinese PLA General Hospital, Beijing Medical Award Foundation | Bladder urothelial carcinoma | | | | |
NCT04871321: Biomarker Discovery in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | N/A | 120 | RoW | nab-paclitaxel plus gemcitabine-cisplatin, immunohistochemistry, NGS, RNA-sequencing, Liquid biopsy | CHA University, Dong-A Pharmaceutical | Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | 03/24 | 12/24 | | |
ChiCTR2100054296: Clinical study of preoperative and postoperative adjuvant tislelizumab in the treatment of recurrent operable head and neck squamous cell carcinoma after radiotherapy |
|
|
| Recruiting | N/A | 30 | China | Tislelizumab combined with cisplatin and paclitaxel | Peking University Stomatological Hospital ; Peking University Stomatological Hospital, Shanghai Lianxiang Public Welfare Foundation | head and neck squamous cell carcinoma | | | | |
ChiCTR2200056151: Efficacy and safety of medical thoracoscopic cryotherapy combined with standard first-line regimen in the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a multicenter, prospective, randomized controlled clinical trial |
|
|
| Not yet recruiting | N/A | 141 | | Medical thoracoscopy cryotherapy for malignant pleural effusion ;Sequential intrapleural infusion of cisplatin/erythromycin ;Only the intrapleural tube was used to drain pleural effusion, and the local pleural cavity was not treated. | The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital; The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Self-financing | Lung cancer | | | | |
NCT05595408: Circulating Tumour DNA and Urine Tumor DNA Detection of Minimal Residual Disease in Locally Advanced Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy: A Cohort Study |
|
|
| Recruiting | N/A | 103 | RoW | Adjuvant chemotherapy, adjuvant immunotherapy | RenJi Hospital, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University, West China Hospital, Xiangya Hospital of Central South University, Peking University First Hospital, Shanghai 10th People's Hospital, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Soochow University, Tianjin Medical University Second Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The Affiliated Hospital of Medical School of Ningbo University, Yantai Yuhuangding Hospital, Nanjing Medical University Affiliated Cancer Hospital, The First Affiliated Hospital, Zhejiang University School of Medicine, Lihuili Hospital, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongda Hospital Affiliated to Southeast University | Muscle Invasive Upper Tract Urothelial Carcinoma | 12/23 | 12/24 | | |
NCT05291403: Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion |
|
|
| Recruiting | N/A | 141 | RoW | Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer, Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer, Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment | Qianfoshan Hospital | Non Small Cell Lung Cancer | 12/23 | 12/24 | | |
NCT04402593: Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients With rGCC: A Pilot Study |
|
|
| Withdrawn | N/A | 15 | US | Modified Heidelberg Model of Neuro-Music Therapy | Indiana University | Relapsed Germ Cell Cancer, Cisplatin Induced Tinnitus | 12/23 | 12/24 | | |
| Recruiting | N/A | 48 | Europe | Anthracyclines, Trastuzumab, Cisplatin, Bleomycin | University Medical Center Groningen | Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related | 01/25 | 01/25 | | |
NCT06197126: MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy |
|
|
| Not yet recruiting | N/A | 200 | RoW | Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) ., concurrent chemothearpy | Fujian Cancer Hospital | Cervical Cancer, Radiotherapy, Prognostic Model, MRI | 12/27 | 12/28 | | |
NCT06267144: Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Sintilimab plus chemotherapy | The First Hospital of Jilin University | Lung Cancer | 06/25 | 12/25 | | |
NCT06224894: The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children |
|
|
| Not yet recruiting | N/A | 80 | NA | Music Therapy, antiemetic treatment | Bilecik Seyh Edebali Universitesi | Music Therapy, Nausea, Anxiety, Cancer, Vomiting, Children, Only | 10/24 | 02/25 | | |
NCT06256224: Toripalimab Combined With Definitive CCRT for LACC Patients |
|
|
| Recruiting | N/A | 150 | RoW | Toripalimab, CCRT | Ruijin Hospital | Cervical Cancer, Chemoradiotherapy, Immunotherapy | 12/28 | 12/28 | | |
NCT06019520: Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity |
|
|
| Active, not recruiting | N/A | 70 | RoW | N-Acetylcysteine, Chemotherapy | Foundation University Islamabad | Drug Toxicity | 02/24 | 03/24 | | |
NCT06313450: De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 112 | RoW | de-escalated radiotherapy, conventional radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY | 02/26 | 02/28 | | |
| Recruiting | N/A | 278 | Europe | Radiochemotherapy plus interventional radiotherapy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Vaginal Cancer | 03/26 | 12/28 | | |
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. |
|
|
| Recruiting | N/A | 150 | RoW | Hypofractionated radiotherapy/SBRT（5-8 Gy/fx，3-5 fx）, Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin, Gemcitabine and Albumin paclitaxel | Zhejiang Cancer Hospital | Gastroesophageal Junction Adenocarcinoma, Liver Cancer Stage IV, Biliary Tract Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Gastric Cancer | 12/25 | 12/25 | | |
NCT06323265: A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 50 | RoW | Adebrelimab + chemotherapy, ±chest radiotherapy | Hebei Medical University Fourth Hospital | Extensive Stage Small Cell Lung Cancer | 04/25 | 04/26 | | |
| Recruiting | N/A | 150 | Europe | Cisplatin, Cis-diammine-dichloroplatinum, Platinol, Carboplatin, Paraplatin | Fundación GECP | Stage IIIA Non-small Cell Lung Cancer | 03/24 | 04/24 | | |
| Recruiting | N/A | 120 | RoW | CCRT, control group: CCRT + observation, Paclitaxel, Cisplatin, trial group: CCRT + adjuvant chemotherapy | Chongqing University Cancer Hospital | Cervical Cancer | 04/24 | 04/29 | | |
| Recruiting | N/A | 40 | Europe | blood draws | University Medical Center Groningen | HNSCC, Head and Neck Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer | 04/24 | 04/24 | | |
NCT06197776: Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC |
|
|
| Not yet recruiting | N/A | 50 | RoW | cisplatin-based chemoradiotherapy combined with immunotherapy | Sun Yat-sen University | Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy | 12/25 | 12/26 | | |
NCT06364046: Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC |
|
|
| Not yet recruiting | N/A | 56 | RoW | Drug-eluting beads bronchial arterial chemoembolization, Serplulimab, Intravenous chemotherapy | The Central Hospital of Lishui City | Carcinoma, Small Cell Lung Cancer | 12/24 | 12/25 | | |
ChiCTR2000031511: Efficacy and safety of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in elderly patients with locally advanced nasopharyngeal carcinoma: a prospective II phase clinical trial |
|
|
| Recruiting | N/A | 36 | | induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy | Affiliated Cancer Hospital of Guangzhou Medical University; Affiliated Cancer Hospital of Guangzhou Medical University, Self-raised | nasopharyngeal carcinoma | | | | |
| Completed | N/A | 101 | Europe | | University Medical Center Groningen | Testicular Cancer | 04/24 | 04/24 | | |
HGT-QoL, NCT05889585: Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant |
|
|
| Recruiting | N/A | 180 | Europe | | Gustave Roussy, Cancer Campus, Grand Paris | Germ Cell Tumor | 05/24 | 05/24 | | |
NCT06302465: Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells |
|
|
| Recruiting | N/A | 60 | RoW | narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide, doxorubicin、cisplatin、methotrexate、ifosfamide | Peking University People's Hospital | Malignant Bone Tumor | 11/26 | 12/26 | | |
NCT06373055: Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics |
|
|
| Recruiting | N/A | 250 | RoW | neoadjuvant chemotherapy followed by radical cystectomy | Yonsei University | Muscle-invasive Bladder Cancer | 11/33 | 11/33 | | |
NCT05879796: Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer |
|
|
| Not yet recruiting | N/A | 30 | NA | cis-platinum, Cisplatin, radiation, External beam radiotherapy, Brachytherapy, Envafolimab Injection, KN035, Recombinant Human Endostatin Injection, endostar | Peking University Third Hospital | Cervical Cancer | 05/24 | 05/26 | | |
NCT06420908: Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | N/A | 30 | NA | Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy | Hebei Medical University Fourth Hospital | Esophageal Squamous Cell Carcinoma | 05/26 | 05/27 | | |
NCT04465942: Immunotherapy in Lung Cancer: Treatment After IO Cessation. |
|
|
| Recruiting | N/A | 300 | Europe | (chemo)immunotherapy, cisplatinum, carboplatinum, pemetrexed, paclitaxel, pembrolizumab, nivolumab, atezolizumab | European Lung Cancer Working Party | Carcinoma, Non-Small-Cell Lung, Immunotherapy | 06/24 | 06/25 | | |
MOSAIC, NCT05933863: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance |
|
|
| Recruiting | N/A | 200 | RoW | PD-(L)1 antibody immunotherapy | Peking University Cancer Hospital & Institute | SCLC,Extensive Stage | 06/24 | 12/24 | | |
EMPHATIC, NCT06434493: Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 30 | NA | Proton Beam Therapy, Concurrent oral capecitabine chemotherapy, Cisplatin & Gemcitabine intravenous chemotherapy, Orthotropic Liver Transplant | The Christie NHS Foundation Trust, University College London Hospitals, University College, London, Royal Free Hospital NHS Foundation Trust | Cholangiocarcinoma | 01/28 | 01/29 | | |
ChiCTR2200064159: Stereotactic body radiotherapy combined with paclitaxel/cisplatin and triplimumab in the treatment of stage IV driver gene-negative non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | 60 | | standard treatment combined with SBRT ;Immunotherapy combined with chemotherapy | Jinshan Hospital Affiliated to Fudan University; Jinshan Hospital Affiliated to Fudan University, Wu Jieping Medical Foundation | Non small cell lung cancer | | | | |
NCT05873790: Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study |
|
|
| Not yet recruiting | N/A | 30 | NA | Serplulimab plus chemotherapy | The First Hospital of Jilin University | Lung Cancer | 06/24 | 12/24 | | |
NCT06447454: Combining Chemoradiotherapy With Sintilimab in First-Line ICC |
|
|
| Not yet recruiting | N/A | 19 | RoW | radiotherapy, RT, gemcitabine + cisplatin, GC, slulimumab, HLX10 | Shanghai Zhongshan Hospital | ICC | 12/26 | 12/28 | | |
| Recruiting | N/A | 452 | RoW | Lymph node dissection, Standard chemoradiation, Chemoradiation | Chongqing University Cancer Hospital, Sun Yat-sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangxi Provincial Cancer Hospital, Anhui Provincial Cancer Hospital, The Second Affiliated Hospital of Harbin Medical University, Hebei Medical University Fourth Hospital, Zhejiang Cancer Hospital, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Fujian Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Cancer Hospital of Guizhou Province, West China Second University Hospital, Tongji Hospital, The Affiliated Ganzhou Hospital of Nanchang University, First Affiliated Hospital of Gannan Medical University, Gansu Provincial Maternal and Child Health Care Hospital, Third Affiliated Hospital of Xinjiang Medical University, Affiliated Cancer Hospital of Shantou University Medical College, Obstetrics & Gynecology Hospital of Fudan University, The Second Affiliated Hospital of Dalian Medical University, Fujian Maternity and Child Health Hospital | Cervical Cancer | 08/24 | 08/29 | | |
CECIL, NCT05701735: Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer |
|
|
| Recruiting | N/A | 45 | RoW | CECIL Patient Decision Aid, Decision Support Intervention | University of Santo Tomas Hospital, Philippines, University of Santo Tomas - Graduate School, University of Santo Tomas - Faculty of Medicine and Surgery, University of Santo Tomas Hospital - Benavides Cancer Institute, Philippine Council for Health Research & Development, Manila Doctors Hospital, Our Lady of Lourdes Hospital | Locally Advanced Cervical Carcinoma | 09/24 | 12/24 | | |
NCT01453660: Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls |
|
|
| Active, not recruiting | N/A | 44 | US | Endo-PAT2000 testing, For any patients in Surgery-Only Group who relapse & enroll in the the, Cisplatin-Based Chemotherapy Group before the completion of the Surgery Group, End of Study Assessment, the Baseline Time 1 Chemotherapy Group Assessment can, will also serve as the End of Study Time 5 Surgery Group Assessment. | Memorial Sloan Kettering Cancer Center | Germ Cell Cancer | 10/24 | 10/24 | | |
| Recruiting | N/A | 37 | RoW | HITOC | Shanghai Zhongshan Hospital | Thymic Epithelial Tumor | 11/24 | 11/25 | | |
NCT05717790: Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 288 | RoW | Nimotuzumab, h-R3, BIOMAb EGFR, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Fourth Affiliated Hospital of Guangxi Medical University, People's Hospital of Baise, Second Affiliated Hospital of Guangzhou Medical University, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin Medical University, China, LiuZhou People's Hospital, The First People's Hospital of Qinzhou, Wuzhou Red Cross Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities | Nasopharyngeal Carcinoma by AJCC V8 Stage | 11/24 | 11/27 | | |
NCT05217212: Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer? |
|
|
| Recruiting | N/A | 100 | Europe | Radiochemotherapy | Luzerner Kantonsspital, Universität Luzern | Head and Neck Squamous Cell Carcinoma | 12/24 | 12/25 | | |
NeoCon-F, NCT04016389: FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery |
|
|
| Recruiting | N/A | 90 | Canada, US | Cisplatin, Carboplatin, Paclitaxel, Trachelectomy | University Health Network, Toronto, Hotel Dieu Hospital, The Netherlands Cancer Institute | Cervical Cancer | 12/24 | 06/25 | | |
CC3, NCT04678791: Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma |
|
|
| Not yet recruiting | N/A | 286 | RoW | Nimotuzumab, EGFR monoclonal antibody, Cisplatin, Cisplatin injection, External-beam radiation, Brachytherapy | Peking University Third Hospital | Cervical Squamous Cell Carcinoma | 12/24 | 12/25 | | |
ChiCTR2100053385: A study evaluating the conversion therapy of surufatinib in combination with chemotherapy in patients with unresectable pancreatic neuroendocrine tumor (PNET) |
|
|
| Recruiting | N/A | 24 | | Surufatinib+Capecitabine + Temozolomide ;Surufatinib+Etoposide+cisplatin | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | pancreatic neuroendocrine tumor | | | | |
ChiCTR2200061313: A prospective, single-arm, single-center, phase II pilot study of sintilimab (IBI308) combined with chemotherapy as induction therapy for locally advanced head and neck squamous cell carcinoma |
|
|
| Recruiting | N/A | 288 | | Sintilimab ;Docetaxel ;cisplatin ;RT | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NA | Squamous cell carcinoma of head and neck | | | | |
NCT04544969: Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC |
|
|
| Recruiting | N/A | 50 | RoW | cisplatin-based chemotherapy, docetaxel and cisplatin, fluorouracil and cisplatin, docetaxel, fluorouracil and cisplatin, gemcitabine and cisplatin | Sun Yat-sen University | Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy | 12/24 | 12/25 | | |
NCT05800054: Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer |
|
|
| Recruiting | N/A | 210 | RoW | Nutritional Support Team, taixinsheng, Docetaxel, chemotherapy, cisplatin, Radiotherapy | The First Affiliated Hospital with Nanjing Medical University | Esophageal Neoplasms, Adverse Drug Event | 12/24 | 12/27 | | |
NCT05916690: Electrochemotherapy for the Treatment of Vulvar Cancer |
|
|
| Recruiting | N/A | 20 | Europe | Electrochemotherapy with bleomycin or cisplatin | Institute of Oncology Ljubljana | Vulvar Cancer | 12/24 | 12/25 | | |
ChiCTR2200067166: A phase II, randomized controlled clinical study based on single-cell sequencing to explore the clinical predictive value of immune cell subsets in the treatment of locally advanced cervical cancer patients with or without tislelizumab combined with concurrent chemoradiotherapy |
|
|
| Not yet recruiting | N/A | 18 | China | tislelizumab + Cisplatin combined with radiotherapy ;Cisplatin combined with radiotherapy | Union Hospital of Tongji Medical College, Huazhong University of Science and Technology ; Union Hopistal Tongji Medical College, Huazhong University of Science and Technology, self-funded | cervical carcinoma | | | | |
NCT04638465: De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 150 | US | Transoral robotic surgery, Cisplatin - Dose Level 1, Cisplatin - Dose Level 2, Dose Level 1, Dose Level 2 | Nebraska Methodist Health System | HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, Oropharynx Cancer | 01/25 | 01/30 | | |
NCT05884905: Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration |
|
|
| Recruiting | N/A | 100 | RoW | short hydration, short intravenous fluid infusion, conventional hydration, long intravenous fluid infusion | Mahidol University, Siriraj Hospital | Renal Insufficiency, Cis-Platinum Nephropathy | 01/25 | 03/25 | | |
ChiCTR2200056354: Neoadjuvant Tislelizumab, followed by surgery and adjuvant chemoradiotherapy in locally advanced oral cavity or oropharynx squamous cell carcinoma: An open-label clinical trial |
|
|
| Recruiting | N/A | 30 | China | Neoadjuvant therapy: Tislelizumab, cisplatin, paclitaxel. Surgery. Adjuvant therapy: RT or cCRT. | Peking University Hospital of Stomatology ; Peking University Hospital of Stomatology, National clinical key discipline construction project | oral cavity or oropharynx carcinoma | | | | |
PET-BOOST, NCT02788461: Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy |
|
|
| Active, not recruiting | N/A | 78 | Canada | Chemoradiotherapy, Chemoradiotherapy with Integrated Boost Dose | Lawson Health Research Institute | Non-Small Cell Lung Cancer | 04/25 | 04/25 | | |
ChiCTR2200060391: Prospective, single arm clinical study of pabolizumab combined with cisplatin + 5-FU in neoadjuvant therapy for unresectable and advanced temporal bone squamous cell carcinoma |
|
|
| Recruiting | N/A | 30 | | The patient received four cycles of pabolizumab (200 mg intravenous drip, 21 day cycle) combined with 5-FU (500 mg/m2 intravenous drip) + cisplatin (80 mg/m2 intravenous drip, 21 day cycle). | Sun Yat Sen Memorial Hospital; Sun Yat Sen Memorial Hospital, self-funded | unresectable and advanced temporal bone squamous cell carcinoma | | | | |
ChiCTR2200060972: The safety and efficacy of Terezumab combined with Docetaxel and Cisplatin in treating patients with resectable esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 62 | | Terezumab combined with Docetaxel and Cisplatin | Army medical center; Army medical center, self-raised | local advanced esophageal squamous cell carcinoma | | | | |
NCT04378023: Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. |
|
|
| Recruiting | N/A | 34 | Europe | Neoadjuvant Chemo-radiotherapy, Liver Transplantation | Hospital Vall d'Hebron | Unresectable Cholangiocarcinoma | 06/25 | 06/25 | | |
GOETH, NCT03917173: Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Gastric Carcinoma. Study |
|
|
| Recruiting | N/A | 240 | Europe | Surgery plus HIPEC CO2, Standard surgery | Mario Negri Institute for Pharmacological Research | Stomach Neoplasms | 06/25 | 06/25 | | |
NCT05352321: Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 264 | RoW | Gemcitabine, Cisplatin, regular intensity-modulated radiotherapy, surgery, Endoscopic nasopharyngectomy, Retropharyngeal lymphadenectomy, Neck lymph node dissection, Target-reduction intensity-modulated radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/25 | 06/28 | | |
AURACCO, NCT05946577: Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study |
|
|
| Not yet recruiting | N/A | 140 | Europe | | Assistance Publique - Hôpitaux de Paris | Head Cancer, Neck Cancer | 06/25 | 09/26 | | |
OrganoHIPEC, NCT06057298: Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases |
|
|
| Recruiting | N/A | 24 | Europe | Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Peritoneal Metastases From Colorectal Cancer | 06/25 | 06/25 | | |
NCT05775419: Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC |
|
|
| Recruiting | N/A | 1216 | RoW | Consolidation chemotherapy (4 courses), Concurrent chemotherapy (2 courses) | The First Affiliated Hospital with Nanjing Medical University | Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug | 06/25 | 06/28 | | |
NCT05644249: PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer |
|
|
| Recruiting | N/A | 37 | Europe | Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy, PIPAC | Vilnius University, Vilnius University Hospital Santaros Klinikos, National Cancer Institute (NCI) | Gastric Cancer, Peritoneal Carcinomatosis | 06/25 | 10/27 | | |
| Recruiting | N/A | 30 | Europe | External beam radiation therapy: IMRT/VMAT, Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, External beam radiation therapy: IMPT, Intensity Modulated Proton Therapy, Cisplatin, Brachytherapy | Leiden University Medical Center, Erasmus Medical Center, HollandPTC | Uterine Cervical Neoplasms, Locally Advanced Cervical Carcinoma | 07/25 | 12/26 | | |
ChiCTR2000034748: Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase II and observational clinical study |
|
|
| Not yet recruiting | N/A | 264 | China | Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 ;Standard IMRT radiotherapy ;Tislelizumab 200mg, IV, q3w, the day before radiotherapy | Cancer Hospital, Fudan University ; Cancer Hospital, Fudan University, sponsorship | recurrent cervical cancer | | | | |
ChiCTR2200063209: Efficacy and safety of Sintilimab combined with pegylated recombinant human granulocyte colony stimulating factor in the treatment of metastatic NSCLC |
|
|
| Not yet recruiting | N/A | 100 | | Carrelizumab 200mg, paclitaxel 135mg/m2, cisplatin 75mg/m2 or carboplatin AUC5 intravenous drip, combined with pegylated recombinant human granulocyte stimulating factor 6mg subcutaneously, once every 3 weeks ;Carrelizumab 200mg, paclitaxel 135mg/m2, cisplatin 75mg/m2 or carboplatin AUC5 were administered intravenously once every 3 weeks | Department of Oncology, the Eighth People's Hospital of Jinan ; the Eighth People's Hospital of Jinan, self-raised | Lung cancer | | | | |
| Recruiting | N/A | 30 | RoW | Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy | Peking Union Medical College Hospital | Cervical Neoplasm, Adaptive Radiotherapy, Radiotherapy; Adverse Effect | 09/25 | 12/25 | | |
NCT04772001: Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer |
|
|
| Recruiting | N/A | 53 | RoW | Hydrochloride anlotinib, cis Platinum/carboplatin, External beam radiotherapy and brachytherapy | Zhongnan Hospital | Uterine Cervical Neoplasms, Chemoradiotherapy, Angiogenesis | 10/25 | 01/26 | | |
SYSUGO-005, NCT02624531: Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(/CSEM009) |
|
|
| Recruiting | N/A | 60 | RoW | Taxane, cisplatin, radical trachelectomy, simple trachelectomy, conization, sentinel node biopsy | Sun Yat-sen University | Cervical Cancer | 11/25 | 11/25 | | |
NCT05494190: The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 111 | RoW | Docetaxel, Cisplatin, Capecitabine, Concomitant chemoradiotherapy, Surgery | Eye & ENT Hospital of Fudan University, Shandong Provincial Hospital, Harbin Medical University Third Affiliated Hospital | Hypopharyngeal Carcinoma | 11/25 | 11/25 | | |
QoLATI, NCT04124198: Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 138 | Europe | Intensity-Modulated Radiation Therapy (IMRT), Cisplatin, Nimorazole., Transoral Robotic Surgery (TORS) with neck dissection | Christian von Buchwald, Naestved Hospital, Herlev Hospital, Aarhus University Hospital, Odense University Hospital | Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Carcinoma, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Pharyngeal Neoplasms Malignant and Unspecified, Otorhinolaryngologic Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Diseases, Pharyngeal Diseases, Papillomavirus Infections, Virus Diseases, DNA Virus Infections, Tumor Virus Infections, Quality of Life | 12/25 | 01/29 | | |
ChiCTR2000041222: The mechanism of SMYD3 promotes cisplatin resistance in ovarian cancer |
|
|
| Recruiting | N/A | 60 | | Nil | Cancer Hospital Affiliated to Zhengzhou University; Cancer Hospital Affiliated to Zhengzhou University, self-raised Marchds | non-small cell lung cancer | | | | |
| Recruiting | N/A | 380 | RoW | Cervical cancer, Uterine cancer, Cervical cancer, pelvic sidewall invasion, Non-cervical cancer, pelvic sidewall invasion | Seoul National University Hospital | Cervical Cancer, Uterine Cancer | 12/25 | 12/25 | | |
ChiCTR2200057679: The Study of a New Bladder Sparing Treatment Modality including Endoscopic Balloon Cryoablation and Adjuvant Immunotherapy for High-risk Bladder Cancer |
|
|
| Not yet recruiting | N/A | 210 | | endoscopic balloon cryoablation ;transurethral resection of bladder tumor ;immune checkpoint inhibitor ;chemotherapy (gemcitabine and cisplatin) ;radical cystectomy | Department of Urology，Huashan Hospital Fudan University; Huashan Hospital Fudan University, Shanghai Shenkang Hospital Development Center | bladder cancer | | | | |
NCT05622474: A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy |
|
|
| Not yet recruiting | N/A | 236 | RoW | Induction chemotherapy plus Concurrent chemotherapy, Concurrent chemotherapy, IMRT | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan | Nasopharyngeal Carcinoma | 12/25 | 12/28 | | |
NCT05667415: Treatment of Advance Gastric Cancer With Disulfiram |
|
|
| Not yet recruiting | N/A | 40 | RoW | disulfiram and cisplatin, cisplatin | First People's Hospital of Hangzhou, College of Pharmaceutical Sciences at Zhejiang University, The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University | Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram | 12/25 | 06/26 | | |
ChiCTR2000039569: A prospective cohort study on whether proton pump inhibitors aggravate cisplatin-induced acute renal injury |
|
|
| Recruiting | N/A | 260 | | PPIs and Cisplatin ;Cisplatin | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, In-hospital subsidy | Acute renal injury | | | | |
NCT05831917: MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer |
|
|
| Recruiting | N/A | 41 | RoW | Radiotherapy | Sichuan Cancer Hospital and Research Institute | HNSCC | 01/26 | 01/26 | | |
ChiCTR2100043156: A prospective, randomized, controlled clinical trial to evaluate the efficacy and safety of interval debulking surgery combined with cisplatin and docetaxel hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer |
|
|
| Recruiting | N/A | 190 | | Cisplatin intraperitoneal hyperthermia intraperitoneal chemotherapy ;cisplatin and docetaxel hyperthermic intraperitoneal chemotherapy | Beijing Shijitan Hospital, Capital Medical University; Level of the institution：, Beijing Hospitals Authority' Ascent Plan, Code: DFL20190701 | ovarian cancer | | | | |
| Recruiting | N/A | 600 | Canada | Questionnaire, sampling of blood, urine and saliva | The Hospital for Sick Children, Canadian Institutes of Health Research (CIHR), London Health Sciences Centre, Provincial Health Services Authority | Acute Kidney Injury, Cancer | 04/26 | 12/28 | | |
PARCERII, NCT05857631: Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study |
|
|
| Recruiting | N/A | 90 | RoW | Hypofractionated Image guided External Beam Radiation Therapy (EBRT), Radiotherapy, Cisplatin, Chemotherapy, Vaginal brachytherapy, Brachytherapy | Tata Memorial Centre | Cervical Cancer, Endometrial Cancer | 05/26 | 05/29 | | |
NCT04588168: Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma |
|
|
| Recruiting | N/A | 100 | RoW | Chemotherapy, Neoadjuvant chemotherapy, Immediate Multiparametric MRI, Multiparameter magnetic resonance imaging, Cystectomy and Lymphadenectomy, surgery, conventional Multiparametric MRI, Baseline Multiparametric MRI | The First Affiliated Hospital with Nanjing Medical University | Bladder Cancer | 06/26 | 06/26 | | |
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | N/A | 367 | RoW | chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo | Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital | Lung Cancer | 06/26 | 06/26 | | |
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial) |
|
|
| Recruiting | N/A | 8300 | US, RoW | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT | National Cancer Institute (NCI) | Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8 | 09/26 | 09/26 | | |
NCT05903703: Canagliflozin With Gemcitabine in Pancreatic Carcinoma |
|
|
| Not yet recruiting | N/A | 20 | RoW | Canagliflozin and Gemcitabine, Gemcitabine | Zhang Xiaofeng,MD, College of Pharmaceutical Sciences at Zhejiang University, The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University | Pancreatic Cancer | 09/26 | 03/27 | | |
NCT06120374: Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC |
|
|
| Recruiting | N/A | 300 | RoW | Radiotherapy, Chemotherapy and immunotherapy, Combined adjuvant therapy | Peking University First Hospital | Urothelial Carcinoma | 10/26 | 10/28 | | |
ChiCTR1900025150: Paclitaxel combined with cisplatin versus fluorouracil combined with cisplatin in the treatment of locally advanced esophageal squamous cell carcinoma: a prospective, open, randomized, multicenter clinical study. |
|
|
| Not yet recruiting | N/A | 580 | | taxol 135-175 mg/m2/d d1+ cisplatin 75mg/m2/d d1 q21d ;38/5000 Cisplatin: 75mg/m2 d1, 5-fu: 750mg/m2 CIV24h d1-4 | Nanyang Central Hospital; Nanyang Central Hospital, self-raised | Esophageal squamous cell carcinomas | | | | |
NCT05378087: Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer |
|
|
| Recruiting | N/A | 1956 | RoW | Concurrent chemoradiation, Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation | Chongqing University Cancer Hospital | Locally Advanced Cervical Cancer | 04/27 | 12/32 | | |
ChiCTR2000034072: Prospective, multicenter randomized controlled clinical study of radical concurrent chemotherapy and radiotherapy combined with PD-1 antibody SHR-1210 in the treatment of stage III-IVA cervical cancer |
|
|
| Recruiting | N/A | 172 | | Radiation therapy + 5 cycles of cisplatin concurrent chemotherapy + Carrizumab ;Cisplatin + concurrent radiotherapy | Southern Hospital of Southern Medical University; Southern Hospital of Southern Medical University, Self-raising | Cervical cancer | | | | |
NCT05517135: Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study |
|
|
| Recruiting | N/A | 1000 | RoW | Arm 1, Arm 2, Arm 3, Group 1, Group 2 | National Cancer Centre, Singapore | Nasopharyngeal Carcinoma | 07/27 | 07/27 | | |
NCT06101966: A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy |
|
|
| Not yet recruiting | N/A | 500 | RoW | external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) | Fujian Cancer Hospital | Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model, Risk Factor | 12/27 | 12/27 | | |
ChiCTR1800015101: A Radiomics-based nomogram for Stratifying bladder cancer of Receiving Neoadjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 300 | | chemotherapy combining gemcitabine and cisplatin for 6 weeks and receive radical cystectomy ;receive radical cystectomy without neoadjuvant chemotherapy | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-sen University Cancer Center, Natural Science Foundation of China (81572514, U1301221, 81472384, 81372729) | Bladder cancer | | | | |
| Recruiting | N/A | 100 | Canada | High-Dose Cisplatin, Low-Dose Cisplatin, Radiotherapy | Lawson Health Research Institute | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/28 | 09/28 | | |
